Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erdafitinib + Palbociclib + Fulvestrant in FGFR-amplified MBC
NCT03238196Phase 1Completed
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Aug 2017
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of erdafitinib in breast cancer (2 cohorts), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoint: Dose Limiting Toxicities at 4 weeks. Started Aug 2017; status: completed.
02
Drugs
erdafitinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03238196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03238196.